published meta-analysis   sensitivity analysis   studies

nirmatrelvir / ritonavir (Paxlovid) in COVID 19 outpatients - Summary of results

OutcomeTE95% CInkI2ROBPub. bias death D28detailed resultsEPIC-HR, 2021 0.04 [0.00; 0.70] 0.04[0.00; 0.70]EPIC-HR, 202110%2,085NAnot evaluable deathsdetailed resultsEPIC-HR, 2021 0.04 [0.00; 0.70] 0.04[0.00; 0.70]EPIC-HR, 202110%2,085NAnot evaluable hospitalization or deathdetailed resultsEPIC-HR, 2021 0.12 [0.06; 0.24] 0.12[0.06; 0.24]EPIC-HR, 202110%2,085NAnot evaluable related AE (TRAE)detailed resultsEPIC-HR, 2021 1.76 [1.10; 2.82] 1.76[1.10; 2.82]EPIC-HR, 202110%1,349NAnot evaluable related SAE (TRSAE)detailed resultsEPIC-HR, 2021 1.01 [0.25; 4.05] 1.01[0.25; 4.05]EPIC-HR, 202110%1,349NAnot evaluable0.05.01.0relative treatment effectwww.metaEvidence.org2024-03-29 07:06 +01:00

TE: relative treatment effect (measured by a risk ratio, an odds ratio or an hazard ratio depending on what is reported in the papers); k: number of studies; n: total number of patients; ROB: risk of bias (ROB 2.0); Pub. bias: publication bias; OBS: observational studies; RCT: randomized clinical trials
studied treatment is better when TE > 1; studied treatment is better when TE < 1;

pathologies: 97 - treatments: 1250 - roots T: 290